O4 Hubs detail
O4 Detail Hero Banner

Drug Pipeline Insights Report

3 new drugs to watch this fall

Are these new gene therapies worth the price?​

By Sumit Dutta, MD, Chief Medical Officer at Optum Rx | Published: October 2022

O4 1 Column (Full)
O4 Text Component

Welcome to the fall edition of Drugs to Watch.

O4 2 Columns (2/3 - 1/3)
O4 1 Column (Full)
O4 Text Component

As the year begins to close, we highlight three essential pipeline drugs with an expected U.S. Food and Drug Administration (FDA) decision this fall.

Two of the three drugs discussed have an Orphan Drug designation while the third was granted Priority Review. In today's market, we are seeing new orphan drugs more frequently and expect this trend to continue. However, you may be surprised by the price tag.

The drugs in this report include treatments for:

  • Kidney disease
  • Inherited bleeding disorder
  • Eye disease

View report

Don't want to read the full report? Download the brief summary.

View summary

Related content

O4 Complex Card

Gene therapy: How to prepare for a growing pipeline

The unprecedented cost of gene therapies requires a fundamental rethinking of how treatment costs are managed.
O4 Complex Card

8 ways to make drugs more affordable

Discover what plan sponsors need to know.
O4 Complex Card

5 questions: Optum Rx chief pharmacy officer

Michael Einodshofer addresses the risks, challenges and opportunities facing the industry.